21.05.2008 20:00:00
|
New Analysis Showed That High Dose Lipitor Can Reduce the Risk of Cardiovascular Events in Bypass Surgery Patients
Pfizer Inc announced today that Lipitor®
(atorvastatin calcium) 80 mg significantly reduced the risk of major
cardiovascular events, including heart attack and stroke, by 27 percent
in patients with heart disease who had previous coronary bypass surgery
compared with patients taking the 10 mg dose of Lipitor. This analysis,
designed and completed following the closure of the five-year Treating
to New Targets (TNT) study, was published in the "Journal
of the American College of Cardiology.”
Intensive Lipitor therapy also provided a significant 30 percent
reduction in the need for either repeat coronary bypass surgery or
angioplasty, another type of interventional heart surgery, compared with
Lipitor 10 mg.
Each year in the U.S., approximately 470,000 bypass surgeries are
performed on 270,000 people. Patients in the TNT study who had undergone
previous bypass surgery had a much higher likelihood of cardiovascular
events than those who did not have prior bypass surgery. This especially
high risk population tends to be under-treated with lipid-lowering
therapy.
"Patients may be under the impression that
once they have had coronary bypass surgery, they are no longer at high
risk for heart attacks and strokes,” said Dr.
Rochelle Chaiken, vice president of Pfizer’s
global cardiovascular and metabolic medical team. "Although
these patients continue to be at an increased risk for major
cardiovascular events and repeat heart surgery, statins are considerably
underused. This analysis highlights not only the importance of treating,
but also treating aggressively with Lipitor 80 mg.”
Both doses of Lipitor (80 mg and 10 mg) were well-tolerated in patients
with prior coronary bypass surgery, and the safety profile of Lipitor 80
mg was comparable to Lipitor 10 mg, a finding that was consistent with
the overall TNT population.
About the TNT Study
The TNT study was an investigator-led trial coordinated by an
independent steering committee and funded by Pfizer. The primary
endpoint was the reduction of major cardiovascular events, including
death from heart disease, non-fatal heart attacks, resuscitated cardiac
arrest, and fatal or non-fatal strokes.
The study enrolled 10,001 men and women with coronary heart disease aged
35 years to 75 years in 14 countries and followed them for an average of
five years. In this analysis, 4,654 patients who had previous coronary
bypass surgery were compared with 5,347 patients who did not. Lipitor 80
mg is not a starting dose.
About Coronary Bypass Surgery
Coronary bypass surgery is a procedure in which damaged sections of the
coronary arteries (arteries that bring blood to the heart muscle) are
replaced with healthy blood vessel segments. The surgery reroutes, or
"bypasses," blood around clogged arteries to improve blood flow and
oxygen to the heart.
This procedure is done because arteries that bring blood to the heart
muscle can become clogged by plaque (a buildup of fat, cholesterol and
other substances). This can slow or stop blood flow through the heart's
blood vessels, leading to chest pain or a heart attack. Increasing blood
flow to the heart muscle can relieve chest pain and reduce the risk of
heart attack.
About Angioplasty
Angioplasty is a type of interventional heart surgery which encompasses
a variety of procedures used to treat patients with diseased arteries of
the heart, such as:
Chest pain caused by a build-up of fats and cholesterol.
Other substances from the blood (referred to as plaque) that can
reduce blood flow to a near trickle.
A heart attack caused by a large blood clot that completely blocks the
artery.
Typically, angioplasty is performed by threading a slender
balloon-tipped tube – a catheter –
from an artery in the groin to a trouble spot in an artery of the heart.
The balloon is inflated, compressing the plaque and widening the
narrowed coronary artery so that blood can flow more easily. This is
often accompanied by inserting an expandable metal stent (a small mesh
tube) to keep the artery open.
About Lipitor
Only Lipitor offers these three benefits important in a statin: FDA
approval to reduce the risk of heart attacks, strokes and other
cardiovascular events in patients with or without heart disease; the
ability to reduce "bad”
cholesterol (LDL) by 39 percent to 60 percent; and a well-established
safety profile across a broad range of patients.
It is the most prescribed cholesterol-lowering therapy in the world,
with nearly 151 million patient-years of experience. Lipitor is
supported by a 15-year clinical trial program involving more than 400
ongoing and completed trials with more than 80,000 patients.
Important U.S. Prescribing Information
Lipitor is a prescription medication. It is used in patients with
multiple risk factors for heart disease such as family history, high
blood pressure, age, low HDL ("good" cholesterol) or smoking to reduce
the risk of heart attack, stroke, certain kinds of heart surgery, and
chest pain.
Lipitor is used in patients with existing coronary heart disease to
reduce the risk of heart attack, stroke, certain kinds of heart surgery,
hospitalization for heart failure, and chest pain.
Lipitor is also used in patients with type 2 diabetes and at least one
other risk factor for heart disease such as high blood pressure, smoking
or complications of diabetes, including eye disease and protein in
urine, to reduce the risk of heart attack and stroke.
When diet and exercise alone are not enough, Lipitor is used along with
a low-fat diet and exercise to lower cholesterol.
Lipitor is not for everyone. It is not for those with liver problems.
And it is not for women who are nursing, pregnant or may become pregnant.
Patients taking Lipitor should tell their doctors if they feel any new
muscle pain or weakness. This could be a sign of rare but serious muscle
side effects. Patients should tell their doctors about all medications
they take. This may help avoid serious drug interactions. Doctors should
do blood tests to check liver function before and during treatment and
may adjust the dose. The most common side effects are gas, constipation,
stomach pain and heartburn. They tend to be mild and often go away.
For additional product information, visit www.Lipitor.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Pfizer Inc.mehr Nachrichten
Analysen zu Pfizer Inc.mehr Analysen
14.11.24 | Pfizer Neutral | UBS AG | |
01.11.24 | Pfizer Neutral | UBS AG | |
30.10.24 | Pfizer Buy | Goldman Sachs Group Inc. | |
29.10.24 | Pfizer Buy | Jefferies & Company Inc. | |
24.10.24 | Pfizer Neutral | JP Morgan Chase & Co. |
Aktien in diesem Artikel
Pfizer Inc. | 24,57 | 0,74% |
Indizes in diesem Artikel
Dow Jones | 44 722,06 | -0,31% | |
S&P 500 | 5 998,74 | -0,38% | |
S&P 100 | 2 883,15 | -0,41% | |
NYSE US 100 | 17 376,20 | -0,02% |